Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Travere Therapeutics, Inc. (NASDAQ:TVTX) has earned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $30.62.

Several analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a research report on Friday, February 21st. Scotiabank lifted their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. Citigroup lifted their price target on Travere Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, February 24th. HC Wainwright lifted their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. lifted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th.

Travere Therapeutics Trading Up 3.1 %

Shares of NASDAQ TVTX opened at $19.73 on Friday. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -4.81 and a beta of 0.75. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock’s 50 day simple moving average is $20.33 and its 200 day simple moving average is $17.71.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The business had revenue of $74.79 million during the quarter, compared to analyst estimates of $72.38 million. Equities research analysts expect that Travere Therapeutics will post -1.4 EPS for the current year.

Insider Transactions at Travere Therapeutics

In other news, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $19.10, for a total value of $39,460.60. Following the completion of the sale, the insider now owns 59,883 shares of the company’s stock, valued at $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 206,335 shares of company stock valued at $4,453,012 over the last quarter. Company insiders own 3.75% of the company’s stock.

Institutional Trading of Travere Therapeutics

Institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Travere Therapeutics during the fourth quarter valued at $31,000. Sterling Capital Management LLC boosted its position in Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after purchasing an additional 2,115 shares during the last quarter. R Squared Ltd acquired a new stake in Travere Therapeutics during the fourth quarter valued at $53,000. Gen Wealth Partners Inc acquired a new stake in Travere Therapeutics during the fourth quarter valued at $73,000. Finally, Quarry LP acquired a new stake in Travere Therapeutics during the third quarter valued at $105,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.